A recent study published in the Journal of Affective Disorders has shed new light on the role of sleep improvement in predicting the success of transcranial magnetic stimulation (TMS) treatment for major depressive disorder (MDD). The study, which involved a group of researchers from various organisations, including the James A. Haley Veterans Hospital and the University of South Florida, represents the largest sample size to date looking at the connection between sleep dysfunction and TMS treatment outcomes for depression.
Major depressive disorder is a prevalent mental health issue, disproportionately affecting veterans. Traditional treatments, such as psychopharmacology and psychotherapy, often result in limited success, with only about one-third of patients achieving remission. TMS, an FDA-approved, non-invasive treatment, has emerged as a viable option for those with treatment-resistant depression (TRD). TMS works by using electromagnetic energy to stimulate specific areas of the brain, particularly the left dorsolateral prefrontal cortex, to alter cortical excitability and related neural circuits.
Sleep dysfunction is a common symptom of MDD, affecting up to 90% of patients, and has been linked to poorer treatment outcomes. The SPIRiTeD study aimed to explore whether improvements in sleep dysfunction during TMS treatment could predict better outcomes in depressive symptoms.
The study was a retrospective observational cohort study involving 854 veterans who received TMS treatments through the “VA TMS Clinical Pilot Program” over three years. Sleep dysfunction was assessed using the Patient Health Questionnaire (PHQ-9) sleep item. The researchers analysed the association between sleep improvements during TMS treatment and depression outcomes, with data collected at baseline, week 1, week 3, and week 6 of treatment.
The study found that 94.3% of the veterans reported sleep dysfunction at baseline. Improvements in sleep were significantly associated with higher rates of depression remission at all three time points. Specifically, veterans who experienced sleep improvement had remission rates of 27.84% at week 1, 29.32% at week 3, and 30.99% at week 6, compared to much lower rates among those who did not report sleep improvement.
Moreover, the severity of baseline sleep dysfunction correlated with remission rates. Veterans with the most severe sleep dysfunction at baseline had lower remission rates, suggesting that persistent sleep dysfunction could hinder depression recovery.
These findings suggest that sleep improvement could serve as a predictive marker for the efficacy of TMS treatment in MDD. The study supports the notion that addressing sleep dysfunction early in TMS treatment might enhance overall treatment outcomes for depression. The researchers hypothesise that sleep dysfunction and depressive disorders exist as parallel processes, where improvement in one can positively influence the other.
This study’s results are particularly relevant for clinicians seeking to optimise TMS treatment protocols. Interventions aimed at improving sleep, such as cognitive behavioural therapy for insomnia (CBTi) or pharmacological sleep aids, could potentially be integrated with TMS treatment to maximise therapeutic benefits.
The study had several limitations inherent to its retrospective design. The primary measure of sleep dysfunction was a single item from the PHQ-9, which may not capture the full complexity of sleep disorders. Additionally, the study did not control for all possible confounding factors, such as comorbid medical and psychiatric conditions or the use of sleep aids.
